Lykos Therapeutics Restructures to Focus on Resubmission of NDA for PTSD Treatment Midomafetamine

Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, today announced a reorganization to best support the company as...

August 16, 2024 | Friday | News
Alcura Receives MIA License for Cell and Gene Therapies, Expanding CGT Support Across Europe

Alcura, a provider of specialized clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) lic...

August 15, 2024 | Thursday | News
Eisai and Biogen Announce Middle East Approval of Alzheimer’s Drug LEQEMBI® (lecanemab) in the UAE

Eisai Co., Ltd. and Biogen Inc. are pleased to announce that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved the hum...

August 15, 2024 | Thursday | News
BioSenic Secures Key Japanese Patent for Enhanced Arsenic-Based Therapeutics in Autoimmune and Cancer Treatments

Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...

August 14, 2024 | Wednesday | News
Mangoceuticals Secures 20-Year Patent in India for Innovative Preventive Health Technology

Mangoceuticals, Inc. \ a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of ...

August 14, 2024 | Wednesday | News
Shanghai Junshi Biosciences’ Toripalimab sNDA Accepted by NMPA for First-Line Treatment of Advanced Melanoma

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

August 13, 2024 | Tuesday | News
FDA Approves First Non-Injection Epinephrine Nasal Spray, Neffy, for Life-Threatening Allergic Reactions

U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those th...

August 12, 2024 | Monday | News
Thermo Fisher Scientific's SeCore™ CDx HLA A Sequencing System Receives FDA Clearance as Companion Diagnostic for Adaptimmune’s TECELRA® TCR Therapy

Thermo Fisher Scientific Inc., the world leader in serving science,  announced that its SeCore™ CDx HLA A Sequencing System has been granted 5...

August 07, 2024 | Wednesday | News
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy

Agilent that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovia...

August 05, 2024 | Monday | News
FDA Grants Accelerated Approval for TECELRA in Advanced Synovial Sarcoma Treatment

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment ...

August 02, 2024 | Friday | News
FDA Grants Priority Review to Vertex's Suzetrigine, Targeting January 2025 for Action Date

FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine...

July 30, 2024 | Tuesday | News
MSD Announces Positive CHMP Opinion for KEYTRUDA® and Padcev® Combo in Advanced Urothelial Carcinoma

MSD (NYSE: MRK), known as Merck & Co., Inc. in the United States and Canada, today announced that the European Medicines Agency’s Committee for...

July 29, 2024 | Monday | News
European Commission Approves AbbVie’s SKYRIZI® for Treatment of Moderately to Severely Active Ulcerative Colitis

AbbVie announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely ac...

July 29, 2024 | Monday | News
NOVIO's INO-3107 Achieves EMA Certification for Recurrent Respiratory Papillomatosis Treatment

NOVIO a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related disease...

July 26, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close